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Chemokine response to febrile urinary tract infection.
Background. Mucosal CXC chemokines recruit inflamma-
tory cells to the infected urinary tract. The chemokine response
repertoire of the urinary tract and the relationship to disease
severity have not been examined, however.
Methods. This study quantified CXC (CXCL1, CXCL3,
CXCL5, CXCL8, CXCL9, and CXCL10) and CC (CCL2,
CCL4, and CCL5) chemokines in sequential urine samples ob-
tained from 50 patients with febrile urinary tract infections dur-
ing 24 hours after diagnosis.
Results. All patients had elevated chemokine levels, but bac-
teremic infections caused higher CXCL1, CXCL3, CXCL5,
CXCL8, and CCL2 responses. CCL2 and CXCL8 levels were
higher in patients with acute pyelonephritis symptoms and
CCL2, CXCL3, CCL4, CXCL5, and CXCL10 were signifi-
cantly correlated to C-reactive protein (CRP) and temperature.
Women and men showed different chemokine responses.
Conclusion. Febrile urinary tract infections are accompanied
by a complex chemokine response. The response magnitude re-
flects disease severity, and the repertoire is influenced by gender
and underlying disease.
The diverse manifestations of urinary tract infection
reflect the quality, localization, and magnitude of the in-
flammatory response to pathogenic bacteria [1]. Acute
pyelonephritis is accompanied by local symptoms from
the upper urinary tract like flank pain or costoverte-
bral angle tenderness and by fever and malaise reflecting
the systemic involvement. The temperature or circulat-
ing acute-phase reactants like C-reactive protein (CRP)
are used to quantify the systemic inflammatory response,
but there is no tradition of measuring local host response
parameters in urine, even though the local repertoire of
inflammatory mediators reflects both the site and severity
of infection.
Chemokines are small chemotactic proteins of 8 to
10 kD, that selectively target and activate specific cell
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populations and attract them to inflamed tissue sites [2].
They are divided into four subgroups (CXC, CC, C, and
CX3C), based on the arrangement of the first two of four
conserved cysteine residues. The CXC family is further
subdivided according to the sequence glutamic acid-
leucine-arginine (ELR) near the N-terminus immedi-
ately preceding the first cysteine residue. ELR containing
CXC chemokines are potent neutrophil activators and
include CXCL1, CXCL3, CXCL5, and CXCL8 [previ-
ously referred to as GROa, GROc, ENA-78, and inter-
leukin (IL)-8]. CXC chemokines lacking the ELR motif,
CXCL9 and CXCL10 (previously referred to as Mig and
IP-10), have a weak if any neutrophil-activating activity,
but attract and activate T cells and natural killer (NK)
cells. CC chemokines like CCL2 [previously referred to
as monocyte chemoattractant protein-1 (MCP-1)], CCL4
(previously referred to as MIP-1b), and CCL5 [previ-
ously referred to as regulated upon activation, normal
T-cell expressed and secreted (RANTES)] attract mostly
monocytes and T cells, but also neutrophils [3, 4].
Urinary tract infections elicit a mucosal chemokine re-
sponse [5–8]. Epidemiologic studies of symptomatic in-
fections showed elevated urine and serum CXCL8 levels
in patients with febrile urinary tract infection [5, 7, 9–
15], and both CXC and CC chemokines were detected in
patients with urosepsis [12, 15, 16]. In pediatric popula-
tions, the urinary tract chemokine response was shown
to be specific for febrile urinary tract infection, as ele-
vated urine CXCL8 levels were detected in children with
febrile urinary tract infection but not in those with febrile
infection of unknown origin [11]. The first chemotactic
signal emanates from uroepithelial cells which are effi-
cient chemokine producers [17, 18] (for review see [19]).
Uropathogenic Esherichia coli stimulate a chemokine
response through different TLR4-dependent signaling
pathways in the epithelial cells [20–22]. P fimbriae are
one essential virulence factor, as shown by the rapid
CXCL8 response to deliberate intravesical inoculation
of the human urinary tract with P fimbriated E. coli
[23, 24] and by the lack of chemokine production dur-
ing long-term asymptomatic carriage of the nonfimbri-
ated strain. The chemokine response is essential for the
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antibacterial defense of the urinary tract, and especially
the CXC chemokines are crucial to recruit inflammatory
cells to infected sites within the urinary tract [12, 18, 25–
27].
The earlier studies have shown that virulent strains
trigger a urinary tract chemokine response in patients
with symptomatic urinary tract infection, but have not
addressed how the chemokine repertoire reflects disease
severity. This study investigated the chemokine response
in patients with febrile urinary tract infection, the effect
of bacteremia and the relationship to disease severity.
METHODS
Patients
Fifty patients with community-acquired febrile urinary
tract infection were included in this study [28]. The pa-
tients were 18 to 85 years old, with febrile urinary tract
infection requiring hospitalization and parenteral antibi-
otic therapy. All patients had significant bacteriuria at
admission, a temperature ≥38◦C, and either focal symp-
toms from the urinary tract, a positive nitrite test at
admission, increased leukocyte counts in urine, or instru-
mentation of the urinary tract/acute urinary retention
preceding the onset of fever. The patients were hospi-
talized and treated with parenteral ceftazidime [28]. Pa-
tients with bacteremic febrile urinary tract infection had
at least one positive blood culture with the same bacterial
species in blood and urine. Symptoms, signs, and medical
history were registered by standardized questionnaire.
The patients assigned to the compromised group had
diabetes, chronic lymphocytic leukemia, systemic lupus
erythematodes, alcoholism, Morbus Crohn, cancer, treat-
ment with corticosteroids, or urinary tract abnormalities.
Patients with urinary tract abnormalities had prostatic hy-
perplasia, operations of the urogenital tract, renal stones,
prolapse of the uterus, urinary tract devices, indwelling
urinary catheter, intermittent catheterization or an artifi-
cial urinary sphincter. Focal symptoms from the upper
urinary tract included flank pain, costovertebral angle
tenderness and symptoms from the lower urinary tract
included dysuria, frequency, and suprapubic pain.
The study was approved by the Research Ethics Com-
mittee of the Medical Faculty, at the University of Lund.
Bacterial cultures
Freshly voided urine samples were semiquantitatively
cultured. Blood samples for aerobic and anaerobic cul-
ture were taken twice at inclusion [29]. Significant bac-
teriuria was defined by growth of a single bacterial species
at ≥104 cfu/mL in women and ≥103 cfu/mL in men.
Host response parameters
Blood and urine samples were obtained at inclusion,
and at 6 to 8, 12 to 14, and 24 hours after the onset of
antibiotic therapy. Serum and urine samples were imme-
diately frozen at −70◦C. CRP was quantified at inclusion,
after 12, 24, and 48 hours, and on day 3. Total white blood
cell counts, neutrophil counts, erythrocyte sedimentation
rate (ESR), and orosomucoid were analyzed at inclusion
and on day 3.
Urine leukocytes were microscopically counted in cen-
trifuged urine. Pyuria was defined as ≥5 leukocytes/
microscopic field, and abundant pyuria as≥30 leukocytes/
microscopic field.
Chemokine assays
Antigenic CXCL1, CXCL3, CXCL5, CXCL8, CXCL9,
CXCL10, CCL2, CCL4, and CCL5 were quantified us-
ing a modification of the double ligand method previ-
ously described [30, 31]. Briefly, flat bottomed 96-well
microtiter plates were coated with 50 lL/well of the ap-
propriate polyclonal antibodies for 24 hours at 4◦C. Sam-
ples were added, followed by incubation for 1 hour at
37◦C. Biotinylated polyclonal rabbit antihuman CXCL1,
CXCL3, CXCL5, CXCL8, CXCL9, CXCL10, CCL2,
CCL4, and CCL5 antibodies were added (50 lL/well),
and incubated for 45 minutes at 37◦C followed by
streptavidin-peroxidase conjugate for 30 minutes at 37◦C.
Chromogenic substrate was added, and the reaction was
terminated with 3 mol/L H2SO4 (50 lL/well). Plates were
read at 490 nm in an automated microplate reader (Bio-
Tek Instruments, Inc., Winooski, VT, USA). The enzyme-
linked immunosorbent assay (ELISA) detects cytokine
concentrations >10 pg/mL. The chemokine concentra-
tions were determined in urine samples obtained at in-
clusion, and 6, 12, and 24 hours after onset of antibiotic
therapy. The 24 hours peak value was the highest concen-
tration recorded during the first 24 hours after onset of
antibiotic therapy.
Statistics
The Mann-Whitney U test, the Wilcoxon signed ranks
test for paired data, the Fisher exact test and the Pearson
correlation test were used. P values <0.05 were consid-
ered statistically significant (two-tailed).
RESULTS
Patients
Patients with febrile urinary tract infection were en-
rolled in the study [28]. Twenty-four patients with bac-
teremia and 26 nonbacteremic patients were matched ac-
cording to gender, age (±10 years) and date of inclusion in
the study. E. coli were found in 47 patients and Citrobacter
64 Otto et al: Chemokine responses in febrile urinary tract infection
Table 1. Host background variables, symptoms, host response parameters, and urine culture data at inclusion
Febrile urinary tract infection
Nonbacteremic Bacteremic
Host background variables
Men/women number 13/13 10/14
Age years median (range) 64 (23-82) 69 (29-85)
Complicating diseasea number (%) 16 (62.0) 17 (71.0)
History of other urinary tract diseaseb number (%) 15 (58.0) 11 (46)
Use of urinary tract devicesc number 2 5
Symptoms
Dysuria, frequency, urgency number (%) 17 (70.8) 13 (54.2)
Flank pain, costovertebral angle tenderness number (%) 13 (50.0) 13 (54.0)
Hypotension number 1 2
Host response parameters, median (range)
Temperature ◦C 39.2 (38.0-40.6) 39.9 (38.2–41.0)
Fever duration before enrollment days 2.0 (0.2–4.0) 1.0 (0.25–8.0)
C-reactive protein mg/L 96 (12–280) 148 (30–344)
Erythrocyte sedimentation rate mm/hour 54 (6–81) 50 (10–87)
White blood cell count ×109/L 11.5 (3.7–19) 13 (4.4–23)d
Urine culture data number (%)
Escherichia coli 26 (100) 21 (87.5)
Non-E. coli 0 (0) 3 (12.5)e
aDiabetes mellitus, chronic lymphocytic leukemia, treatment with corticosteroids, systemic lupus erythematodes, ethylism, Morbus Crohn, cancer with or without
urinary tract abnormalities, prostatic hyperplasia, operations of the urogenital tract, renal stones, prolapse of the uterus, urinary tract devices, multiple sclerosis with
bladder dysfunction, cancer of the prostate.
bProstatic hyperplasia, operations of the urogenital tract, renal stone, prolapse of the uterus, urinary tract devices.
cIndwelling urinary catheter (N = 4) (3 ≥ 4 weeks), intermitted catherization, artificial urinary sphincter.
dThe white blood cell count of one patient with chronic lymphatic leukemia is not included (96.0 × 109)
eKlebsiella pneumoniae (N = 1), Citrobacter freundii (N = 1), Proteus mirabilis (N = 1).
freundii, Klebsiella pneumoniae, or Proteus mirabilis in
three patients. Pyuria was detected in 89% of the patients,
and in 72% pyuria was abundant. The host background
variables, symptoms, and the acute phase response to in-
fection are described in Table 1. The bacteremic patients
had higher temperatures at inclusion (median 39.9◦C vs.
39.2◦C) (P < 0.01) and higher CRP concentrations from
12 hours after the onset of therapy, but there was no dif-
ference in host background variables or focal symptoms
between the bacteremic and nonbacteremic groups. The
study population included 27 women and 23 men with
median ages of 49 and 73 years, respectively (P < 0.01).
Forty-one percent of the women and 96% of the men
were assigned to the compromised group with other ill-
ness, and urinary tract abnormalities occurred in 15% of
the women and in 96% of the men.
Urine chemokine repertoire
Urine chemokine concentrations were measured at in-
clusion and during the first 24 hours after the onset of
therapy (Fig. 1). Seventy-eight percent of the patients had
elevated levels of all nine measured chemokines. At inclu-
sion, CXCL8 responses were detected in all patients, and
CXCL1 and CXCL3 responses were detected in 98%,
CXCL9, CXCL10, and CCL2 in 96%, CXCL5 in 71%,
CCL5 in 65%, and CCL4 in 59%. CXCL8 and CXCL10
levels were higher than the remaining chemokines at all
time points. The chemokine concentrations declined af-
ter the onset of antibiotic therapy except CCL4, which
lacked therapy-related kinetics (Fig. 2).
There was a marked difference in the chemokine reper-
toire between men and women with febrile urinary tract
infection. The women had higher CCL2 responses than
the men at all times (Fig. 4). They also had higher con-
centrations of CXCL1 at 6 and 24 hours and higher peak
24-hour values.
Chemokine response and disease severity
The chemokine response magnitude varied with the
disease severity. Bacteremia was accompanied by higher
urine chemokine concentrations than nonbacteremic in-
fections (Fig. 3). CCL2 was higher throughout the 24-hour
period, CXCL3 during the first 12 hours, CXCL5 from 6
hours, and CXCL1 and CXCL8 at 12 hours. The level
of the other chemokines did not differ between patients
with or without bacteremia, however, and there was no
difference in the chemokine repertoire between the bac-
teremic and the nonbacteremic groups.
The frequency of focal urinary tract symptoms is shown
in Table 1, and the chemokine response in relation to
symptoms in Table 2. Twenty-six patients had clinical
signs of acute pyelonephritis, such as flank pain and
costovertebral angle tenderness. Fourteen patients had
symptoms only from the lower urinary tract, such as dy-
suria, frequency, and urgency. The CCL2 concentrations
were higher in the patients with acute pyelonephritis
symptoms as compared to the group with symptoms only
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Fig. 1. Urine chemokine concentrations in 50 patients with febrile urinary tract infection. Samples were obtained at inclusion and during the first
24 hours after the onset of antibiotic therapy. The peak 24-hour values represent the highest concentrations in each patient during this period. Dots
represent values from individual patients and the horizontal bars the median in each group. Chemokines are not usually detected in urine from
uninfected and otherwise healthy individuals.
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Fig. 2. Decline in urine chemokine concentrations after onset of ther-
apy. Values are in percent of the concentration at inclusion and group
means at 6 and 24 hours are shown. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001,
Wilcoxon signed ranks test for paired data. CXCL1 (×), CXCL3 (∗),
CXCL5 (), CXCL8 ( ), CXCL9 (), CXCL10 (), CCL2 (+), CCL4
( ), and CCL5 ().
from the lower urinary tract (P < 0.01). The CXCL8 con-
centrations behaved in a similar way at some time points.
The remaining chemokines did not vary in relation to
focal symptoms.
The chemokine response was examined as a function
of the systemic host response in each patient. Signifi-
cant positive correlations to the maximum body temper-
ature were observed for CCL2, CCL4, CXCL3, CXCL5,
and CXCL10. The CCL2, CCL4, CXCL3, and CXCL10
concentrations were positively correlated to fever dura-
tion after the start of antibiotic therapy (Table 3). CCL2,
CCL4, CXCL3, CXCL5, CXCL9, and CXCL10 were pos-
itively correlated to CRP (Table 4). In patients without
bacteremia, the CXCL8 and CCL5 concentrations were
significantly correlated to the white blood cell counts in
peripheral blood (Table 5).
Chemokine responses and other illness
Thirty-three patients suffered from diseases that might
compromise their resistance to urinary tract infection
(Table 1). Twenty patients were assigned to a group with
urinary tract abnormalities (one woman and 19 men)
and 13 to a group with more complex medical illness
(ten women and three men). The remaining 17 patients
were healthy except for the febrile urinary tract infection
episode (16 women and one man). The CXCL1 and CCL2
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Fig. 3. Chemokine response and bacteremia. Chemokines that were
higher in the bacteremic than in nonbacteremic patients at 12 hours
after onset of therapy are shown (Mann-Whitney U test). ∗P < 0.05;
∗∗P < 0.01.
Table 2. Urine chemokine responses in relation to focal urinary tract
symptoms in febrile urinary tract infection
Chemokine concentration
ng/mL median (range)
Patient group CXCL8 CCL2
Clinical signs of pyelonephritisa 1.45 (0.31–7.70) 0.52 (0.11–2.30)
Lower urinary tract symptomsb 0.88 (0.20–4.10) 0.10c (0.01–1.50)
No focal urinary tract infection 8.90d (0.360–651) 0.52d (0.14–19.2)
symptoms
Note: The comparison is based on the maximum chemokine concentrations in
each patient. No differences were found in CXCL1, CXCL3, CXCL5, CXCL9,
CXCL10, CCL4, and CCL5.
aFlank pain, costovertebral angle tenderness, with or without lower urinary
tract symptoms.
bDysuria, frequency, urgency, but no pyelonephritis symptoms.
cP < 0.01 in comparison with clinical signs of pyelonephritis (Mann-Whitney
U test).
dP < 0.05 in comparison with lower urinary tract symptoms (Mann-Whitney
U test).
concentrations were higher in the patients without com-
promising conditions (Fig. 4). The CXCL3 and CXCL9
concentrations, in contrast, were higher in the patients
with complex medical illness.
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Table 3. Correlation analysis of temperature and fever duration to
urine chemokines
Coefficient of correlation r
Temperature Temperature Fever
Chemokine hours (at inclusion) (day 1) (duration)
CXCL3 at inclusion 0.33c 0.09 0.31c
Peak 24 hours 0.26d 0.12 0.39c
CXCL5 at inclusion 0.10 0.11 0.10
Peak 24 hours 0.26d 0.16 0.15
CXCL10a at inclusion 0.24d 0.29c 0.32c
Peak 24 hours 0.01 0.17 0.22
CCL2b at inclusion 0.12 0.21 0.14
Peak 24 hours 0.23 0.40c 0.24d
CCL4 at inclusion −0.01 0.11 0.30c
Peak 24 hours 0.13 0.28d 0.40c
NOTE: Only chemokines with significant positive correlations are included
in the table. There was no positive correlation of CXCL1, CXCL8, CXCL9, and
CCL5 to temperature.
aMaximum correlation was CXCL10 at 24 hours to temperature day 1 (r =
0.39) (P < 0.05, two-tailed significance) and to fever duration (r = 0.42) (P <
0.05, two-tailed significance).
bMaximum correlation was CCL2 at 12 hours to temperature day 1 (r = 0.40)
(P < 0.05, two-tailed significance) and to fever duration (r = 0.34) (P < 0.05,
two-tailed significance).
cP < 0.05, two-tailed significance (Pearson correlation test).
dP < 0.05, one-tailed significance (Pearson correlation test).
Table 4. Correlation analysis of C-reactive protein and chemokines
Coefficient of correlation r
C-reactive protein C-reactive protein
Chemokine hours at inclusion maximum
CXCL3 at inclusion 0.36a 0.27b
Peak 24 hours 0.25b 0.46a
CXCL5 at inclusion 0.36a 0.43a
Peak 24 hours 0.14 0.04
CXCL9 at inclusion 0 −0.02
Peak 24 hours 0.28b 0.31a
CXCL10 at inclusion 0.14 0.26b
Peak 24 hours 0.15 0.12
CCL2 at inclusion 0.16 0.36a
Peak 24 hours 0.25b 0.43a
CCL4 at inclusion 0.41a 0.36a
Peak 24 h 0.40a 0.43a
NOTE: Only chemokines with significant correlations are included in the
table. There was no positive correlation of CXCL1, CXCL8, and CCL5 to CRP.
aP < 0.05, two-tailed significance (Pearson correlation test).
bP < 0.05, one-tailed significance (Pearson correlation test).
Summary analysis of the chemokine response in relation
to disease severity
CCL2 responses were higher in patients with bac-
teremia and in patients with clinical signs of acute
pyelonephritis and were positively correlated to fever
and CRP. CCL2 was generally high in women, most of
whom had normal urinary tracts, but CCL2 was low in
men, most of whom had urinary tract abnormalities.
The CXCL1 and CXCL3 responses resembled CCL2
in that they were higher in bacteremic patients, and posi-
tively correlated to fever and CRP. CXCL1 was higher in
women than in men while CXCL3 was higher in patients
with complicating diseases.
Table 5. Correlation analysis of chemokines to white blood cell
counts
White blood cells in the nonbacteremic group
Chemokine Hours Coefficient of correlation r
CXCL8 At inclusion 0.29
At 6 hours 0.45a
Peak 24 hours 0.35b
CCL5 At inclusion 0.45a
At 6 hours 0.37b
Peak 24 hours 0.25
NOTE: Only chemokines with significant positive correlations are included.
Results for CXCL3, CXCL5, CXCL9, CXCL10, CCL2, and CCL4 were negative.
aP < 0.05, two-tailed significance (Pearson correlation test).
bP < 0.05, one-tailed significance (Pearson correlation test).
CCL4 and CXCL10 were positively correlated to fever
and CRP, but were not specifically elevated in the bac-
teremic group. CXCL9 was positively correlated to CRP.
CCL5 showed a positive correlation to white blood cells
in patients without bacteremia, but no other association
with CCL5 to the other study variables was detected.
CXCL8 was high in the bacteremic patients but low in
patients with lower urinary tract symptoms. In addition,
CXCL8 was positively correlated to the peripheral blood
white blood cell count in the patients without bacteremia.
DISCUSSION
This study investigated the local chemokine response
repertoire and the magnitude of the chemokine response
in patients with febrile urinary tract infection. Nine CXC
and CC chemokines were elevated at the time of diagno-
sis. CXCL8, CXCL1, CCL2, CXCL3, and CXCL5 were
higher in patients with bacteremia and/or symptoms of
acute pyelonephritis, and were significantly correlated to
fever and CRP in individual patients. We conclude that
febrile urinary tract infections elicit a complex chemokine
response, and that the response magnitude reflects the
disease severity.
The first wave of chemokines in urine originates from
the epithelial cells that form the mucosal barrier [6, 32].
Pathogenic bacteria adhere to the luminal surface of these
cells, as they infect the bladder or the renal pelvis, and
stimulate the production of cytokines and chemokines
[6, 33]. Human uroepithelial cell lines have been shown
to secrete several CXC and CC chemokines following in
vitro challenge with uropathogenic E. coli [G. Godaly,
manuscript in preparation]. In this study, the chemokine
response in patients with febrile urinary tract infection
was shown to agree with the epithelial response reper-
toire in vitro. The results support the hypothesis that
many of the secreted chemokines in urine are of epithelial
origin.
The urine chemokine concentrations were higher in pa-
tients with culture verified bacteremia and the response
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Fig. 4. Chemokine concentrations in relation
to host background variables. (A) Complicat-
ing disease. (B) CXCL1 and CCL2 in relation
to gender (Mann-Whitney U test). ∗P < 0.05;
∗∗P < 0.01.
magnitude varied with parameters of systemic disease
severity. The chemokines thus resembled the urine IL-6
response, which is higher in bacteremic than in nonbac-
teremic patients and shows strong positive correlations
to CRP and temperature [28, 34]. The IL-6 response may
be functionally important as IL-6 can trigger the acute
phase reaction and act as an endogenous pyrogen. In the
present study, the bacteremic patients had higher levels
of CCL2 and the neutrophil-activating CXC chemokines,
but they did not develop a different urine chemokine
repertoire. The temperature, fever duration, and CRP
levels in the entire group were positively correlated to
CCL2, CCL4, CXCL3, CXCL5, CXCL9, and CXCL10,
but while the chemokines did all correlate at some time
point, the timing of correlation differed. Two aspects of
pathogenesis may contribute to these results. The higher
response may reflect the virulence of the P fimbriated
E. coli strains that cause bacteremia, and their ability
to activate a strong mucosal inflammatory response [20,
35]. In addition, the bacteremic infection is likely to ac-
tivate a larger number of cell types, as the bacteria cross
the epithelial barrier, traverse the submucosa, and in-
vade local blood vessels. Mesangial, endothelial, inter-
stitial cells, and renal fibroblasts produce both CXC and
CC chemokines [36, 37], and recruited inflammatory cells
[6] contribute to the later waves of chemokine response.
However, systemic lipopolysaccharide (LPS) injections
in healthy volunteers did not cause a significant increase
in urine chemokine levels, despite a transient increase
in systemic CCL2, CCL4, CXCL1, CXCL5, CXCL8, and
CXCL10 concentrations, suggesting that chemokines are
not simply filtered from blood to urine [12, 16]. Further-
more, we did not detect a different chemokine repertoire
in the bacteremic group, despite the potential for activa-
tion of numerous cell types. We propose that the mucosa
remains the main effect source of chemokines in bac-
teremia and that the higher chemokine response is due
mainly to increased mucosal inflammation.
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The magnitude and repertoire of chemokines differed
between patients with symptoms of acute pyelonephri-
tis or from the lower urinary tract. Especially CCL2 was
higher in patients with pyelonephritis symptoms than in
the remaining group. Elevated CCL2 levels have previ-
ously been observed in patients with inflammatory kid-
ney diseases [37] and after LPS perfusion of isolated kid-
neys [36], suggesting that CCL2 reflects renal involve-
ment. This may indicate that the patients in this study
with high concentrations of CCL2 and CXCL8 but with-
out focal symptoms actually had renal involvement. The
lack of focal symptoms may reflect their age, since these
patients were older than patients with focal pyelonephri-
tis symptoms (median age 79 years versus 50 years), and
acute pyelonephritis symptoms are less common in older
patients [38]. Patients with lower urinary tract symptoms,
on the other hand, did not have a unique chemokine re-
sponse repertoire, suggesting that the bladder contributes
less strongly than the kidneys to the local chemokine
response.
The marked difference in chemokine response reper-
toire between men and women was unexpected and may
reflect gender per se or a difference in urinary tract in-
fection pathogenesis between men and women. The ma-
jority of female patients had structurally normal urinary
tracts, and did not suffer from other diseases that might
predispose to urinary tract infection. Their acute symp-
toms were typical of acute pyelonephritis, and they were
infected with P fimbriated E. coli strains that stimulate
CCL2 production [39]. Most of the men, in contrast, had
urinary tract abnormalities allowing less virulent bacteria
to cause febrile urinary tract infection. A parallel study
has shown that many men were infected with strains lack-
ing P fimbriae [39], and these strains are poor CCL2 in-
ducers in vitro [G. Godaly, manuscript in preparation].
The frequency of immunosuppressive therapy or diseases
did not differ between men and women. We propose that
these differences in chemokine repertoire between men
and women may result from differences in disease patho-
genesis.
The broad chemokine response repertoire provides an
interesting basis to speculate about the different cell types
that may be recruited to the infected urinary tract. Neu-
trophils are the key effector cells of the innate defense,
but other cell types may be involved in enhancing or pre-
venting the tissue damage that accompanies chronic in-
fection. Several neutrophil-activating CXC chemokines
were elevated in the present study. CXCL8 has been
shown to direct the movement of neutrophils across the
renal pelvic epithelium and into the urine [25–27, 40].
Deletion of ELR+ CXC chemokine function in IL-8 re-
ceptor (IL-8R)−/− mice caused subepithelial neutrophil
accumulation in kidneys and later the mice developed
renal scarring [41]. Other CXC chemokines have potent
neutrophil-activating functions, but their contribution to
neutrophil recruitment in the urinary tract has not been
investigated. Neutralizing CXCL1 and CXCL5 antibod-
ies have been shown to partially inhibit the neutrophil
chemotactic activity of urine from patients with urosep-
sis, suggesting that these responses deserve further study
[12]. Lymphocytes are recruited into the kidney during
the later stages of infection, and plasma cells are abun-
dant in the cellular infiltrate during the development of
renal scaring [42] but specific immunity is not involved in
the clearance of acute urinary tract infection [43]. CCL2,
CCL4, and CCL5 might signal the recruitment of mono-
cytes, macrophages, and different lymphocyte popula-
tions, CXCL9 and CXCL10 may attract activated T cells
into the kidneys, and CCL5 might be essential for the
activation of mucosal mast cells.
CONCLUSION
Febrile urinary tract infections are accompanied by a
broad and diverse chemokine response that reflects dis-
ease severity. It is important to consider if the chemokine
response adds a new level of resolution that might be
of use in the diagnosis of urinary tract infection. Urine
CXCL8 may be proposed as a general marker of urinary
tract infection, useful for example in patients where it
may be difficult to distinguish febrile urinary tract infec-
tion from fever of unknown origin with or without bac-
teruria. Urine CCL2 may serve as an indicator of disease
severity, and may confirm kidney involvement, which is
common in otherwise healthy women with febrile urinary
tract infection. Future studies, including the evaluation of
chemokine responses in afebrile urinary tract infection
patients, are needed, however, to address the value of
chemokines as diagnostic tools in urinary tract infection.
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